Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1172 - Microsatellite instability and PDL1 expression in small bowel adenocarcinoma - potential for immune checkpoint inhibitor therapies


09 Oct 2016


Poster display


Muhammad Alvi


Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378


M.A. Alvi1, S. McQuaid1, R. Wilson2, M. Salto-Tellez1

Author affiliations

  • 1 Centre For Cancer Research And Cell Biology, Queen's University Belfast, BT9 7AE - Belfast/GB
  • 2 Centre For Cancer Research And Cell Biology, Belfast City Hospital Northern Ireland Cancer Centre, School of Medicine, Dentistry & Biomedical Science, BT9 7AE - Belfast/GB


Abstract 1172


Small bowel adenocarcinoma (SBA) is a rare disease but incidence rates are on the rise. Management of SBA is challenging as there is a dearth of known molecular markers and the role and type of adjuvant chemotherapy is also not well defined. Expression of PDL1 in microsatellite instable (MSI) colorectal cancer makes an attractive target for immune checkpoint inhibitor therapies. In this study we have tested this hypothesis in SBA.


Using a retrospective 28 patient matched normal-tumour cohort we investigated MSI using a PCR assay looking at five mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27). MSI was called where three or more markers were affected. PDL1 immunohistochemistry was carried out on a Ventana Benchmark XT platform using PD-L1/CD274 (SP142) antibody at 1:40 dilution. Scoring was done separately for epithelial tumour cells along the invasive front, peritumoural lymphoid follicles and intra-tumoural lymphoid cells using four grades: negative (for no staining), low, moderate and high.


Six cases were identified to be MSI. As shown in Table 1 out of these we observed five to have a high PDL1 expression in both peritumoural lymphoid follicles and epithelial tumour cells along the invasive front. We observed low PDL1 expression in intra-tumoural lymphoid cells in all samples.

Case PDL1 expression in MSI small bowel adenocarcinoma cases
Epithelial tumour cells along the invasive front Peritumoural lymphoid follicles Intra-tumoural lymphoid cells
1 high high low
2 high high low
3 high high low
4 high high low
5 high high low
6 negative moderate low


Our study shows that 20% of SBAs are MSI and 80% of these have a high expression of PDL1. This makes these cases an ideal candidate for immune checkpoint inhibitor therapies targeting PDL1.

Clinical trial identification

Legal entity responsible for the study

Queen's Univeristy Belfast


Cancer Research UK, Experimental Cancer Medicine Centre Network, Sean Crummey Memorial Fund, Tom Simms Memorial Fund, Friends of the Cancer Centre and HSC Public Health Agency


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings